(lp0
S'Albany Molecular Research, Inc.  recently purchased by insider ... Post Analyst - 11 hours ago Albany Molecular Research, Inc.  reached 8.11% versus a 1-year low price of $12.45. The stock was last seen 1.89% higher, reaching at $13.46 on Mar. 27, 2017.Albany Molecular Research, Inc.  Reaches $13.20 After 6.00% Down Move ... - Herald KSInvestor Chatter: Looking at Shares of Albany Molecular Research, Inc. (NASDAQ ... - The Standard'
p1
aS'BRIEF-Albany Molecular Research enters into agreement with pharmaceutical ... Reuters - Feb 21, 2017 Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc. * Albany Molecular - agreement to develop, manufacture undisclosed complex parenteral drug product for registration, subsequent&nbsp;...'
p2
aS"Moody's affirms Albany Molecular's B3 CFR following announced acquisition of ... Moodys.com   - May 9, 2016 New York, May 09, 2016 -- Moody's Investors Service  today affirmed Albany Molecular Research Inc.'s  ratings, including its B3 Corporate Family Rating , B3-PD Probability of Default Rating  and the B1 rating on the company's&nbsp;..."
p3
aS'Albany Molecular Research Inc.  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 Albany Molecular Research Inc.  traded on unusually high volume on Mar. 10, as the stock gained 2.63% to close at $13.65.Healthcare Oversold Stocks: Genesis Healthcare, Inc. , Albany ... - Benchmark Monitor'
p4
aS"Albany Molecular Research 4Q Misses Street  Investopedia - Feb 22, 2017 For 2016, the Albany, New York-based company reported non-GAAP net income of $37.1 million, or $0.95 per share, compared to the previous year's net income of $32.97 million, or $0.96 per share.Albany Molecular Research Inc.  Plunges 5.67% on February 22 - Equities.com"
p5
aS'Which insiders are buying Albany Molecular Research, Inc. ? Post Analyst - Mar 27, 2017 Albany Molecular Research, Inc.  reached 6.1% versus a 1-year low price of $12.45. The stock was last seen 1.15% higher, reaching at $13.21 on Mar. 24, 2017.Should You Sell Albany Molecular Research, Inc. Based On Current Broker Views? - NewsDenIn Volatile Markets Do Analysts Think You Should Buy Albany Molecular Research ... - The De Soto Edge'
p6
aS'AMRI to Present at Barclays Global Healthcare Conference PR Newswire  - Feb 23, 2017 ALBANY, N.Y., March 3, 2017 /PRNewswire/ -- Albany Molecular Research Inc.  announced today that William S. Marth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 16&nbsp;...'
p7
aS"Albany Molecular Research, Regeneron Pharmaceuticals upbeat Albany Times Union - Aug 4, 2016 Two of the region's biopharmaceutical companies released second-quarter results on Thursday, giving investors and analysts insight into their strengths and goals midway through the fiscal year."
p8
aS'Albany Molecular Research Inc.  Moves Higher on Volume Spike for March 13 Equities.com - Mar 13, 2017 Albany Molecular Research Inc.  traded on unusually high volume on Mar. 13, as the stock gained 2.64% to close at $14.01.Stock Returns: NeoGenomics Inc  is Beating Albany Molecular ... - CML NewsMover inside Traders Limelight: Albany Molecular Research, Inc.  - Is stories'
p9
aS'Albany Molecular Research enters partnership in marijuana-related therapy studies Albany Times Union - Jun 24, 2016 With a new partnership, Albany Molecular Research, Inc. aims to advance an evolving area in therapeutics - cannabinoids.'
p10
a.